DOCSLIB.ORG

Global Vaccine Action Plan

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Global Vaccine Action Plan Global Vaccine Action Plan 2019 Regional reports on progress towards GVAP-RVAP goals Draft 13 September 2019 Annex to the GVAP review and lessons-learned report 1 Introduction In its Global Vaccine Action Plan (GVAP) Assessment Report 2015, the Strategic Group of Experts on Immunization (SAGE) made the recommendation that “WHO Regional Directors should make sure the progress towards the Global and Regional Vaccine Actions Plans is reviewed annually at Regional Committee meetings as requested in the World Health Assembly (WHA) resolution WHA65.17. Reports prepared at the country level to review and discuss the progress made should be the basis of the discussion.” As part of this process, WHO Regional Offices provide annually a report on the progress made towards the achievement of the GVAP and the Regional Vaccine Actions Plans (RVAP) goals1. The reports summarize the main issues, challenges, successes and opportunities for countries in each respective region in 2018. These reports are collated in an annex of the GVAP review and lessons-learned report. 1 http://www.who.int/immunization/global_vaccine_action_plan/en/ 2 Contents WHO Regional Office for Africa: Progress Report for the African Region WHO Regional Office for the Americas: Progress Report for the Region of the Americas WHO Regional Office for Eastern Mediterranean: Progress Report for the Eastern Mediterranean Region WHO Regional Office for Europe: Progress Report for the European Region WHO Regional Office for South-East Asia: Progress Report for the South-East Asia Region WHO Regional Office for the West Pacific: Progress Report for the West Pacific Region 3 WHO Regional Office for Africa: Progress Report for the African Region Contents 1- Background/Introduction ..................................................................................................................... 4 2- Achievements ....................................................................................................................................... 5 Objective 1: Increase immunization coverage beyond the current levels .............................................................. 5 Objective 2: Complete the interruption of wild poliovirus transmission and ensure virus containment ............... 8 Objective 3: Eliminate measles and advocate for the elimination of rubella and congenital rubella syndrome .... 9 Objective 4: Attain and sustain elimination/control of other vaccine preventable diseases ................................ 10 2- Challenges ........................................................................................................................................... 11 3- Perspectives ........................................................................................................................................ 12 4- Country highlights ............................................................................................................................... 13 Conclusion ............................................................................................................................................... 14 Annex 1: Progress in the attainment by Member States of key targets of the Regional Strategic Plan for Immunization ....................................................................................................................................... 14 Annex 2: Regional Immunization coverage 2013-2018 ....................................................................................... 15 Annex 3 : Immunization financing 2018 ............................................................................................................. 16 Annex 4: DTP3 and MCV1 coverage 2013-2018 ................................................................................................ 16 1- Background/Introduction The 47 countries of the World Health Organization’s (WHO’s) African Region are home to over 1 billion people, with a combined annual birth cohort of over 37 million. The Global Vaccine Action Plan (GVAP) 2011-2020 was developed with a vision of having a world in which all individuals and communities enjoy lives free from vaccine-preventable diseases. Significant progress has been made towards the GVAP goals in the African region. The Africa Regional Strategic Plan for Immunization 2014-2020 (RSPI) which is aligned with the GVAP goals is the main guiding strategic plan for immunization in the African region. The RSPI aims at achieving universal immunisation coverage and reducing mortality and morbidity from vaccine preventable diseases (VPD) by the end of 2020. In January 2017, Heads of State from across Africa signed the Addis Declaration on Immunization (ADI) and committed to ensuring that everyone in Africa, no matter who they are or where they live, can access equitably all the required vaccines. The ADI is recognised as a political and advocacy instrument which is being used to support the implementation of the RSPI at the highest level of government. The Business case for WHO immunization activities on the African continent 2018-2030 was developed in 2017 with the overall objective of mobilizing sufficient resources for WHO to continue supporting all Member States on the African continent to accelerate efforts toward the achievement of the GVAP targets 4 and ADI commitments as well as to mitigate the risks of Global Polio Eradication Initiative (GPEI) and Gavi transitions. In May 2019, the Pan African Parliamentary meeting in Midrand South Africa adopted a resolution on the establishment of an African Parliamentarian Caucus on Immunization, to drive forward the body’s commitment to ensuring that all children across the continent have access to the vaccines they need. This progress report highlights the achievements made so far in expanding access to vaccines in the WHO African region, as well as challenges and perspectives in moving forward the immunization agenda on the African continent. 2- Achievements Objective 1: Increase immunization coverage beyond the current levels Between 2013 and 2018, the Regional coverage for the third dose of the DTP containing-vaccine (DTP3) and the first dose of the measles containing vaccine (MCV1) increased from 70 to 76% and from 70 to 74% respectively as illustrated in Figure 1 Immunization coverage, performance and progress. The coverage increased from 71 to 74% for the third dose of the oral poliovirus vaccine (OPV3) during the same period. Twenty-one countries2 in 2018 achieved the RSPI coverage target of >=90% for DTP3, an increase from the 17 countries in 2013. Fourteen countries3 in 2018 achieved the MCV1 coverage of at least 90% compared to the 15 countries in 2013. The low coverage in the three largest countries4 responsible for around 38% of the total birth cohort in the Region is the major cause of this relatively low progress. Contextual factors which negatively influenced coverage include multiple competing developmental priorities, gaps in country ownership, lack of community engagement, low data reliability and use, limited logistics capacity, inadequate and uneven distribution of the workforce, and weak health systems aggravated by insecurity and disease outbreaks in various countries (e.g. Ebola Virus Disease, yellow fever, meningococcal meningitis, cholera, etc). 2 Algeria, Botswana, Burkina Faso, Burundi, Cabo Verde, Comoros, Eritrea, Eswatini, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mauritius, Rwanda, Sao Tome and Principe, Seychelles, Sierra Leone, Uganda, United Republic of Tanzania and Zambia. 3 Botswana, Cabo Verde, Comoros (the), Eritrea, Gambia, Ghana, Lesotho, Liberia, Mauritius, Rwanda, Sao Tome and Principe, Seychelles, United Republic of Tanzania, Zambia 4 DRC, Ethiopia and Nigeria 5 Figure 1 Immunization coverage, performance and progress Coverage for selected vaccines, 2013-2018 Countries performances, DTP3 & MCV1 coverage, 2018 100 90 80 80 80 80 77 78 80 76 76 76 Cov <50% Cov >50<80% 72 73 75 75 70 71 74 70 70 Cov >=80<90% Cov >=90% 70 71 72 73 60 62 50 49 Coverage(%) 40 MCV1 15 26 4 14 14 30 23 25 34 18 20 10 7 10 Vaccines 0 DTP3 10 2013 2014 2015 2016 2017 2018 5 11 21 Years 0 10 20 30 40 50 BCG DTP3 MCV1 MCV2 PCV3 Number of countries Source: WUENIC 2018 Source: WUENIC 2018 DTP3 coverage, 2013, 2017, 2018 Sub-national coverage: % of districts with at least 80% coverage Source: reported data, JRF 2018 Source: WUENIC 2018 6 New vaccines introduction By the end of 2018, 40 countries in the African region have introduced pneumococcal conjugate vaccine, and the rotavirus vaccine was introduced in 35 countries while the MenAfriVac was introduced in 21 countries in campaign mode and in seven countries through routine immunisation (Figure 2 New Vaccine introduction). On-going studies in several countries in the African Region have demonstrated 38% reduction in rotavirus hospitalizations and substantial reduction in vaccine type invasive pneumococcal disease following introduction of rotavirus vaccines and pneumococcal conjugate vaccine (PCV) respectively. Surveillance for diseases targeted by new vaccines remains a priority because of the need to document the burden of diarrhoea and pneumococcal disease and concerns about serotype replacement. Figure 2 New Vaccine introduction New vaccine introduction status and coverage, 2018 Comparison between OPV3 and Rotavirus coverage, 2018 110 110 90 90 70 70 50 50 30 30 10 10 Mali -10 STP -10 Togo Kenya Eritrea Liberia Ghana Malawi Angola Zambia Burundi Gambia Uganda Lesotho Ethiopia Namibia Rwanda Senegal Eswatini Mauritius
Load more

Recommended publications
  • Immunizations for Preteens
    INVITED COMMENTARY Immunizations for Preteens Emmanuel B. Walter, Richard J. Chung As a part of health supervision visits, all preteens should figure 1. receive the combined tetanus, diphtheria, and pertussis vac- Immunizations Universally Recommended for North cine, the meningococcal conjugate vaccine, the human pap- Carolina Preteens 11-12 Years of Age illomavirus vaccine series, and an annual influenza vaccine. Because levels of vaccine coverage among preteens are gen- Meningococcal conjugate vaccine First dose (to be followed by a second dose at age 16 years). erally suboptimal, strategies for improving coverage should Tetanus, diphtheria, pertussis vaccine be devised and implemented. Human papillomavirus vaccine 3 doses mmunizations are a major component of health supervi- Females – either HPV4 or HPV2 Ision visits for children and adolescents. Because immuni- Males – HPV4 zation recommendations change frequently, Bright Futures, Influenza vaccine an initiative of the American Academy of Pediatrics (AAP) Yearly that promotes the health of children and adolescents, has 2010 [3, 4]. In 2010, only 14 cases were reported in North issued guidelines that refer providers to the Web sites of the Carolina, and 11 of those cases were caused by serogroups Centers for Disease Control and Prevention (CDC) [1] and included in the current vaccine [4]. Although meningococ- the AAP [2] for the most up-to-date immunization sched- cal disease is uncommon, vaccination is critical, because the ules. For no other age group have routine immunization rec- consequences of infection can be devastating. ommendations evolved more rapidly in the past 8 years than In 2005 the US Food and Drug Administration (FDA) for preteens.
    [Show full text]
  • Safety of Immunization During Pregnancy a Review of the Evidence
    Safety of Immunization during Pregnancy A review of the evidence Global Advisory Committee on Vaccine Safety © World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied.
    [Show full text]
  • Pneumococcal Vaccine
    Vaccines for Primary Care Pneumococcal, Shingles, Pertussis Devang Patel, M.D. Assistant Professor Chief of Service, MICU ID Service University of Maryland School of Medicine Pneumococcal Vaccine Pneumococcal Disease • 2nd most common cause of vaccine preventable death in the US • Major Syndromes – Pneumonia – Bacteremia – Meningitis Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 2010 (ORIG) Vaccine Target • Polysaccharide capsule allows bacteria to resist phagocytosis • Antibodies to capsule facilitate phagocytosis • >90 different pneumococcal capsular serotypes • Vaccines contain most common serotypes causing disease Pneumococcal Vaccines Pneumococcal Vaccines • Pneumococcal polysaccharide vaccine (PPSV23; Pneumovax) – Contains capsular polysaccharides – 23 most commonly infecting serotypes • Cause 60% of all pneumococcal infections in adults – Not recommended for children <2 due to poor immunogenicity of polysaccharides Pneumococcal Vaccines • Pneumococcal conjugate vaccine (PCV13, Prevnar) – Polysaccharides linked to nontoxic protein • higher antigenicity – Stimulates mucosal antibody • Eliminates nasal carriage in young children • Herd effect in adults – Reduction in PCV7 serotype disease >90% Prevnar 13 • 2000 - PCV7 approved for infants toddlers • 2010 - PCV13 recommended for infants and toddlers • 2012 – ACIP recommended PCV13 for high- risk adults • 2014 – recommended for adults >65 • 2018 – ACIP will revisit PCV13 use in adults – Childhood vaccines may eliminate
    [Show full text]
  • Full Text (PDF)
    ASSESSMENT: NEUROLOGIC RISK OF IMMUNIZATION Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Gerald M. Fenichel, MD Immunization programs are among the most cost-effective public health measures. They are the first line of defense against infectious disease, and when abandoned, epidemics often follow. Vaccines are biological products and some differences exist from lot to lot. Although no vaccine is 100% effective or safe, modern vaccines have an excellent safety record. Smallpox was eradicated by a global immunization program, and the eradication of poliomyelitis is within reach for the year 2000. Physicians are quick to blame vaccines for adverse neurologic events that follow immunizations. This bias probably originated with the first vaccines for rabies. They were grown in the CNS of mature animals, contained myelin basic protein, and often caused encephalomyelitis. In fact, no vaccine currently licensed for use in the United States is known to cause or exacerbate a demyelinating disorder of the CNS. The United States maintains the most extensive obligatory childhood immunization schedule of any country, but has one of the worst records of infant immunization (table 1). The main reasons for the low immunization rate are deficiencies in health care delivery and access in the public sector. Full immunization is only realized at age 5, when it becomes prerequisite for school entry. Immunization practices are recommended to the Surgeon General by the Advisory Committee on Immunization Practices (ACIP) of the Centers of Disease Control and Prevention. New recommendations of the ACIP are published in Morbidity and Mortality Weekly Reports and are the standard of care for immunization practice.
    [Show full text]
  • Summary Guide to Tetanus Prophylaxis in Routine Wound Management
    Summary Guide to Tetanus Prophylaxis in Routine Wound Management ASSESS WOUND A clean, minor wound All other wounds (contaminated with dirt, feces, saliva, soil; puncture wounds; avulsions; wounds resulting from flying or crushing objects, animal bites, burns, frostbite) Has patient completed a primary Has patient completed a primary tetanus diphtheria series?1, 7 tetanus diphtheria series?1, 7 No/Unknown Yes No/Unknown Yes Administer vaccine today.2,3,4 Was the most recent Administer vaccine and Was the most Instruct patient to complete dose within the past tetanus immune gobulin recent dose within series per age-appropriate 10 years? (TIG) now.2,4,5,6,7 the past 5 years?7 vaccine schedule. No Yes No Yes Vaccine not needed today. Vaccine not needed today. Administer vaccine today.2,4 2,4 Patient should receive next Administer vaccine today. Patient should receive next Patient should receive next dose Patient should receive next dose dose at 10-year interval after dose at 10-year interval after per age-appropriate schedule. per age-appropriate schedule. last dose. last dose. 1 A primary series consists of a minimum of 3 doses of tetanus- and diphtheria- 4 Tdap* is preferred for persons 11 through 64 years of age if using Adacel* or 10 years of containing vaccine (DTaP/DTP/Tdap/DT/Td). age and older if using Boostrix* who have never received Tdap. Td is preferred to tetanus 2 Age-appropriate vaccine: toxoid (TT) for persons 7 through 9 years, 65 years and older, or who have received a • DTaP for infants and children 6 weeks up to 7 years of age (or DT pediatric if Tdap previously.
    [Show full text]
  • YF-VAX® Rx Only AHFS Category
    YF-VAX® Rx Only Laboratory Personnel AHFS Category: 80:12 Laboratory personnel who handle virulent yellow fever virus or concentrated preparations Rx only of the yellow fever vaccine virus strains may be at risk of exposure by direct or indirect Yellow Fever Vaccine contact or by aerosols. (14) DESCRIPTION CONTRAINDICATIONS ® Hypersensitivity YF-VAX , Yellow Fever Vaccine, for subcutaneous use, is prepared by culturing the YF-VAX is contraindicated in anyone with a history of acute hypersensitivity reaction to any 17D-204 strain of yellow fever virus in living avian leukosis virus-free (ALV-free) chicken component of the vaccine. (See DESCRIPTION section.) Because the yellow fever virus embryos. The vaccine contains sorbitol and gelatin as a stabilizer, is lyophilized, and is used in the production of this vaccine is propagated in chicken embryos, do not administer hermetically sealed under nitrogen. No preservative is added. Each vial of vaccine is YF-VAX to anyone with a history of acute hypersensitivity to eggs or egg products due to supplied with a separate vial of sterile diluent, which contains Sodium Chloride Injection a risk of anaphylaxis. Less severe or localized manifestations of allergy to eggs or to USP – without a preservative. YF-VAX is formulated to contain not less than 4.74 log10 feathers are not contraindications to vaccine administration and do not usually warrant plaque forming units (PFU) per 0.5 mL dose throughout the life of the product. Before vaccine skin testing. (See PRECAUTIONS section, Testing for Hypersensitivity Re- reconstitution, YF-VAX is a pinkish color. After reconstitution, YF-VAX is a slight pink-brown actions subsection.) Generally, persons who are able to eat eggs or egg products may suspension.
    [Show full text]
  • Vaccines for Preteens
    | DISEASES and the VACCINES THAT PREVENT THEM | INFORMATION FOR PARENTS Vaccines for Preteens: What Parents Should Know Last updated JANUARY 2017 Why does my child need vaccines now? to get vaccinated. The best time to get the flu vaccine is as soon as it’s available in your community, ideally by October. Vaccines aren’t just for babies. Some of the vaccines that While it’s best to be vaccinated before flu begins causing babies get can wear off as kids get older. And as kids grow up illness in your community, flu vaccination can be beneficial as they may come in contact with different diseases than when long as flu viruses are circulating, even in January or later. they were babies. There are vaccines that can help protect your preteen or teen from these other illnesses. When should my child be vaccinated? What vaccines does my child need? A good time to get these vaccines is during a yearly health Tdap Vaccine checkup. Your preteen or teen can also get these vaccines at This vaccine helps protect against three serious diseases: a physical exam required for sports, school, or camp. It’s a tetanus, diphtheria, and pertussis (whooping cough). good idea to ask the doctor or nurse every year if there are any Preteens should get Tdap at age 11 or 12. If your teen didn’t vaccines that your child may need. get a Tdap shot as a preteen, ask their doctor or nurse about getting the shot now. What else should I know about these vaccines? These vaccines have all been studied very carefully and are Meningococcal Vaccine safe.
    [Show full text]
  • Commonly Administered Vaccines
    Commonly Administered Vaccines CPT CVX Vaccine Type Brand Name Manufacturer PhilaVax Display Name Description Code Code Combination Vaccines Diptheria, tetanus toxoids and acellular pertussis vaccine, Hepati- DTaP-HepB-IPV Pediarix® GlaxoSmithKline 90723 110 DTaP-HepB-IPV tis B and poliovirus vaccine, inactivated Diptheria, tetanus toxoids and acellular pertussis vaccine and DTaP-Hib TriHIBit® Sanofi Pasteur 90721 50 DTaP-Hib (TriHIBit) Haemophilus influenzae type b conjugate vaccine Diptheria, tetanus toxoids and acellular pertussis vaccine, Hae- DTaP-Hib-IPV Pentacel® Sanofi Pasteur 90698 120 DTaP-Hib-IPV mophilus influenzae type b, and poliovirus vaccine, inactivated Diptheria, tetanus toxoids and acellular pertussis vaccine, and DTaP-IPV Kinrix® GlaxoSmithKline 90696 130 DTaP-IPV (KINRIX) poliovirus vaccine, inactivated HepA-HepB TWINRIX® GlaxoSmithKline 90636 104 HepA/B (TWINRIX) Hepatisis A and Hepatitis B vaccine, adult dosage Hepatitis B and Hemophilus influenza b vaccine, for intramuscular HepB-Hib Comvax® Merck 90748 51 Hib-Hep B (COMVAX) use Haemophilus influenza b and meningococcal sero groups C and Y MeningC/Y-Hib Menhibrix® GlaxoSmithKline 90644 148 Meningococcal-Hib vaccine, 4 dose series Diphtheria, Tetanus and Pertussis DTaP Infanrix® GlaxoSmithKline 90700 20 DTaP (INFANRIX) Diptheria, tetanus toxoids and acellular pertussis vaccine DTaP, 5 Pertussis Antigens Daptacel® Sanofi Pasteur 90700 106 DTaP (DAPTACEL) Diptheria, tetanus toxoids and acellular pertussis vaccine Tetanus toxoid, reduced diphtheria toxoid, and acellular
    [Show full text]
  • Review Article Risk of Seizures After Immunization with Vaccine in Children MD MIZANUR RAHMAN1, KANIJ FATEMA 2
    40 BANGLADESH J CHILD HEALTH 2020; VOL 44 (1) : 40-47 Review Article Risk of Seizures after Immunization with Vaccine in Children MD MIZANUR RAHMAN1, KANIJ FATEMA 2 Abstract: Adverse neurological event particularly seizure after vaccination is not uncommon. The most linked vaccines are Diphtheria, Pertussis and Tetanus toxoid (DPT), Measles, Mumps and Rubella (MMR) and other combination vaccines. It is documented that increased febrile seizure after DPT and MMR vaccine is due to increase febrile episodes precipitating seizure and it is time related. Concomitant administration of vaccines cause seizure due to synergistic effect of those vaccines. When these vaccines are given separately, the risk of seizure is decreased. These type of vaccines are MMR + varicella (MMRV), DTaP-HepB-IPV etc. Regarding etiology, genetic mutation is most important. Some genes are closely related to vaccine induced FS and afebrile seizure like SCN1A, SCN2A, IFI44L, PCDH19 etc. Other causes are endotoxin mediated endothelial damage, IL-1â production and non CNS infection. It is well evident that consequences of not giving vaccine are far more than the adverse events. So Vaccinations should be performed without contraindication in children with previous febrile and afebrile seizures with proper counseling. Key words: seizure, febrile seizure (FS), vaccine, epilepsy. Introduction associated with diphtheria and tetanus toxoids and Immunization is an important part of child care whole-cell pertussis (DTwP). One study found that practice and millions of children are vaccinated every vaccination with DPT was associated with an year. The vaccine is generally well tolerated but elevated risk of seizures (relative risk, 3.3; 95 percent transient adverse events like seizures are rarely confidence interval, 1.4 to 8.2).2 In another study, encountered after vaccination.
    [Show full text]
  • Ensuring the World's Poorest Children Benefit from Lifesaving Vaccines
    WHAT WE’RE LEARNING Ensuring the World’s Poorest Children Benefit from Lifesaving Vaccines “Supporting children’s immunization is undoubtedly the best investment we’ve ever made.” —Bill and Melinda Gates Program Area pertussis) vaccine. When GAVI was The Challenge launched, 71 percent of the world’s Global Health Most people in rich nations do not children were receiving DTP vaccine. realize how difficult it is simply to By 2004, the rate had increased to survive early childhood in many parts Our Goal 78 percent. of the world. Every year, more than Prevent needless deaths in the world’s GAVI has concentrated the greatest 10 million children are buried before poorest countries by increasing access percentage of its resources on speeding they reach their fifth birthday. Of these, to basic vaccines and speeding the the introduction of newer, more about 1.4 million die from diseases that introduction of new vaccines. expensive vaccines, including those for existing vaccines can prevent—including hepatitis B, Haemophilus influenzae B measles, pertussis, and tetanus. Another Our Progress in Brief (Hib), and yellow fever. The vaccine 1.1 million die from diseases for which The Global Alliance for Vaccines for hepatitis B, for example, had been we will soon have vaccines. Because and Immunization (GAVI), which widely used in rich countries for childhood death is so frequent, parents the foundation helped to launch in 20 years but was severely underutilized in some countries in Africa and Asia 1999, has made significant progress. in the developing world because of a don’t even name their babies until they Children’s immunization is no longer a lack of political will and the vaccine’s reach several months of age.
    [Show full text]
  • Association Between Thimerosal-Containing Vaccine and Autism
    BRIEF REPORT Association Between Thimerosal-Containing Vaccine and Autism Anders Hviid, MSc Context Mercuric compounds are nephrotoxic and neurotoxic at high doses. Thi- Michael Stellfeld, MD merosal, a preservative used widely in vaccine formulations, contains ethylmercury. Thus it has been suggested that childhood vaccination with thimerosal-containing vac- Jan Wohlfahrt, MSc cine could be causally related to neurodevelopmental disorders such as autism. Mads Melbye, MD, PhD Objective To determine whether vaccination with a thimerosal-containing vaccine is associated with development of autism. IGH DOSES OF MERCURIC COM- Design, Setting, and Participants Population-based cohort study of all children pounds are nephrotoxic and born in Denmark from January 1, 1990, until December 31, 1996 (N=467450) com- neurotoxic.1 Thimerosal, an paring children vaccinated with a thimerosal-containing vaccine with children vacci- organic compound that con- nated with a thimerosal-free formulation of the same vaccine. Htains ethylmercury, has been widely used Main Outcome Measures Rate ratio (RR) for autism and other autistic-spectrum since the 1930s as a preservative in cer- disorders, including trend with dose of ethylmercury. tain vaccines. In the 1990s, an increas- Results During 2986654 person-years, we identified 440 autism cases and 787 cases ing number of different vaccines con- of other autistic-spectrum disorders. The risk of autism and other autistic-spectrum taining thimerosal were introduced in disorders did not differ significantly between children vaccinated with thimerosal- immunization schedules around the containing vaccine and children vaccinated with thimerosal-free vaccine (RR, 0.85 [95% world, and thus the average cumula- confidence interval {CI}, 0.60-1.20] for autism; RR, 1.12 [95% CI, 0.88-1.43] for other tive exposure to thimerosal in infants has autistic-spectrum disorders).
    [Show full text]
  • ADVISORY COMMISSION on CHILDHOOD VACCINES TABLE of CONTENTS December 8, 2017
    ADVISORY COMMISSION ON CHILDHOOD VACCINES TABLE OF CONTENTS December 8, 2017 TAB • ACCV Agenda 1 • ACCV Charter • ACCV Roster • 2017 Meeting Dates • Meeting Minutes 2 o Draft Minutes – September 8, 2017 • Vaccine Injury Compensation Trust Fund Statement 3 o Vaccine Injury Compensation Trust Fund Summary Sheet for the Period of 10/1/2016 – 9/30/2017 • VICP Data and Statistics 4 • Meeting Presentations & Updates 5 o Report from the Division of Injury Compensation Programs 5.1 o Report from the Department of Justice 5.2 o Petitions to Add Injuries to the Vaccine Injury Table Introduction 5.3 o Petition to Add Tics as an Injury to the Vaccine Injury Table 5.4 o Petition to Add Asthma as an Injury to the Vaccine Injury Table 5.5 5.6 o Petition to Add Pediatric Autoimmune Neuropsychiatric Syndrome (PANS), Pediatric Infection-Triggered Autoimmune Neuropsychiatric Disorders (PITANDS), and Pediatric Autoimmune Neuropsychiatric Disorders (PANDAS) as Injuries to the Vaccine Injury Table o Petition to Add Experimental Autoimmune Encephalomyelitis (EAE) and/or 5.7 Acute Demyelinating Encephalomyelitis (ADEM) as injuries to the Vaccine Injury Table 5.8 o Update on the Immunization Safety Office Vaccine Activities (CDC) o Update on the National Institute of Allergy and Infectious Diseases Vaccine 5.9 Activities (NIH) o Update on the Center for Biologics, Evaluation and Research Vaccine 5.10 Activities (FDA) 5.11 o Update from the National Vaccine Program Office • Program Related Articles 6 6.1 o Popular Science, “Why Are We So Bad At Producing The Right
    [Show full text]